Targeting toll-like receptors for drug development: a summary of commercial approaches.
about
IRAK-4 inhibitors for inflammationAssociation of Toll-like receptor signaling and reactive oxygen species: a potential therapeutic target for posttrauma acute lung injury.Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγIL-6-inducing whole yeast-based immunotherapy directly controls IL-12-dependent CD8 T-cell responses.Activation of TLR2 and TLR6 by Dengue NS1 Protein and Its Implications in the Immunopathogenesis of Dengue Virus Infection.Convergent Transcription of Interferon-stimulated Genes by TNF-α and IFN-α Augments Antiviral Activity against HCV and HEV.Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and CancerToll-like receptors in autoimmunity with special reference to systemic lupus erythematosusA unique host defense pathway: TRIF mediates both antiviral and antibacterial immune responses.Toll-like receptor 4 signaling in intracerebral hemorrhage-induced inflammation and injury.IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems.Toll gates to periodontal host modulation and vaccine therapyPattern recognition receptor-dependent mechanisms of acute lung injury.The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.Patented small molecules against psoriasis.A purified recombinant lipopeptide as adjuvant for cancer immunotherapyTargeting TLR/IL-1R signalling in human diseases.Heat-labile enterotoxins as adjuvants or anti-inflammatory agents.Targeting inflammation as a therapeutic strategy in accelerated atherosclerosis in rheumatoid arthritis.Immune adjuvants in early life: targeting the innate immune system to overcome impaired adaptive response.Toll-like receptor modulators: a patent review (2006-2010).Trauma alarmins as activators of damage-induced inflammation.Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties.Toll gates: An emerging therapeutic target.TRIF-dependent TLR signaling, its functions in host defense and inflammation, and its potential as a therapeutic target.Toll-like receptors: promising therapeutic targets for inflammatory diseases.Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases.
P2860
Q28255508-2855AC99-DE60-4C0F-B926-8B05DF891426Q34035581-4BAA6308-970F-4CBD-9DB4-92ADF3161110Q34438411-E2D13E22-CF3F-4048-BFFF-4B14081DA5EFQ35621594-668FC5E7-94F8-4026-8011-AD219CDD2176Q35727211-097BE7A2-8F05-4C77-8D31-3081E02CB502Q36009894-0BB618E9-B562-413B-A1AA-7EC2A554DDF3Q36127825-290392A5-9348-4BBF-A08B-EE0A59A2DB66Q36377747-0BBDCE8A-E48A-4E72-84A9-DBDDA69E8CB6Q36511199-EFAF1870-03F4-48E4-9126-29E0B1C8B185Q36687238-5A726775-BD17-4565-931E-C0C29815895CQ36968268-F9C9F012-595D-4367-A172-31B1BB2E8E9AQ37416211-59A1CAF4-C0A3-4C4F-9E81-013AB1B1787BQ37447260-BB431864-EBF3-4B01-8683-D693DBF5F125Q37530899-8A9B5118-1353-46D0-8D94-3508055E1856Q37535998-DFD8C50D-388E-47CE-BA8F-70B65588FEEBQ37668805-7FC3A769-DD28-4B6A-B83C-46F2CCC3E5C6Q37731951-FCB9D243-E140-467A-86CB-239C49AABA13Q37749719-8252A16F-7D58-441F-854D-CEA9F91B0268Q37765620-849267CE-69C2-4431-A680-A175E0CB1A25Q37773306-A6E15E0F-E6C3-4C11-B594-37F289B4D28BQ37853197-E8A5CDC7-0649-4E85-B52D-07733F01B813Q37996337-3F13A39B-7C42-48DC-8630-A0A7F1907D34Q38058640-16D47150-6DC9-4AA8-A138-24851EBDD1EAQ38333830-6BBD123C-C0C2-49DA-8588-CFD00EA43CCAQ38830698-925CA1BE-23C8-48AC-80D8-95CC44841BBAQ38925152-047A4908-05E5-4F0A-A468-7FCD9A118965Q42961175-98EF4834-CE2F-4B2A-8F2F-C825B47477A3
P2860
Targeting toll-like receptors for drug development: a summary of commercial approaches.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Targeting toll-like receptors for drug development: a summary of commercial approaches.
@en
type
label
Targeting toll-like receptors for drug development: a summary of commercial approaches.
@en
prefLabel
Targeting toll-like receptors for drug development: a summary of commercial approaches.
@en
P2860
P356
P1476
Targeting toll-like receptors for drug development: a summary of commercial approaches.
@en
P2093
Andrew J H Gearing
P2860
P304
P356
10.1038/SJ.ICB.7100102
P577
2007-07-31T00:00:00Z